All In Biotech

Drug Trial Radar · NCT05275374

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)

Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

221

Planned (sponsor's estimate)

Start

Dec 31, 2025

Primary completion

Dec 30, 2027

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Xynomic Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF V600 mutation. This study is divided into three stages: Phase Ia: a dose-escalation phase of XP-102; Phase Ib: a dose-escalation and sample size expansion phase of XP-102 plus trametinib; Phase IIa: an expansion phase of XP-102 plus trametinib.

Conditions

  • Cancer
  • BRAF V600 Mutation
  • Melanoma
  • Colorectal Cancer
  • Thyroid Cancer
  • Nonsmall Cell Lung Cancer

Interventions

  • XP-102Drug

    XP-102 will be administered orally once or twice daily in a continuous regimen.

  • TrametinibDrug

    Trametinib will be administered 2mg orally once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterize the safety of XP-102.Time frame: 28 days
  2. Evaluate the pharmacokinetics of XP-102.Time frame: 28 days
  3. Establish maximum tolerated dose of XP-102.Time frame: 28 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.